Imara Announces Completion of Patient Enrollment in Ardent Phase 2b Clinical Trial of IMR-687 (tovinontrine) for Sickle Cell Disease
05 août 2021 07h15 HE
|
Imara, Inc.
BOSTON, Aug. 05, 2021 (GLOBE NEWSWIRE) -- Imara Inc. (Nasdaq: IMRA), a clinical-stage biopharmaceutical company dedicated to developing and commercializing novel therapeutics to treat patients...
Imara to Webcast Conference Call of Second Quarter 2021 Financial Results and Business Highlights
30 juil. 2021 07h00 HE
|
Imara, Inc.
BOSTON, July 30, 2021 (GLOBE NEWSWIRE) -- Imara Inc. (Nasdaq: IMRA), a clinical-stage biopharmaceutical company dedicated to developing and commercializing novel therapeutics to treat patients...
Imara Announces Recipients of the Second Annual Real Impact Grants Program to Support People Affected by Rare Genetic Blood Disorders
17 juin 2021 07h00 HE
|
Imara, Inc.
BOSTON, June 17, 2021 (GLOBE NEWSWIRE) -- Imara Inc. (Nasdaq: IMRA), a clinical-stage biopharmaceutical company dedicated to developing and commercializing novel therapeutics to treat patients...
Imara to Present Clinical Data on IMR-687 in Sickle Cell Disease at the European Hematology Association (EHA) Annual Congress
04 juin 2021 07h00 HE
|
Imara, Inc.
Oral presentation provides final results from 93-patient Phase 2a trial and additional interim data from open label extension trial Imara to host conference call and live webcast on June 11, 2021 at...
Imara Reports First Quarter 2021 Financial Results and Business Highlights
11 mai 2021 07h00 HE
|
Imara, Inc.
On-track to report interim analyses for both Ardent sickle cell disease and Forte beta-thalassemia Phase 2b clinical trials in the second half of 2021 Completed enrollment in the...
New Report Demonstrates Potential for Cell and Gene Therapies to Provide Cost Savings
10 janv. 2020 11h23 HE
|
Alliance for Regenerative Medicine
WASHINGTON, D.C., Jan. 10, 2020 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- The Alliance for Regenerative Medicine (ARM), the leading international advocacy organization representing the cell and gene...
Vista Partners Updates Coverage on ADVENTRX Pharmaceuticals, Inc.; Target Price $4.50
31 janv. 2013 09h15 HE
|
Vista Partners LLC
SAN FRANCISCO, CA--(Marketwire - Jan 31, 2013) - Vista Partners announced today that it has updated coverage on ADVENTRX Pharmaceuticals, Inc. (NYSE MKT: ANX) ("ADVENTRX" or "ANX") with a twelve...
Vista Partners Updates Coverage on ADVENTRX Pharmaceuticals, Inc.; $3.50 Target Price
12 juil. 2012 09h15 HE
|
Vista Partners
SAN FRANCISCO, CA--(Marketwire - Jul 12, 2012) - Vista Partners announced today that it has updated coverage on ADVENTRX Pharmaceuticals, Inc. (NYSE MKT: ANX) (NYSE Amex: ANX) ("The Company,"...
Vista Partners Publishes May 2012 Newsletter
08 mai 2012 09h15 HE
|
Vista Partners LLC
SAN FRANCISCO, CA--(Marketwire - May 8, 2012) - Vista Partners ("Vista") announced today that it published its FREE macroeconomic/small cap oriented monthly newsletter for the month of May. Each...
HemaQuest Pharmaceuticals Receives Orphan Drug Designations for Therapeutic to Treat Hemoglobin Disorders
04 nov. 2008 09h00 HE
|
HemaQuest Pharmaceuticals
BOSTON, MA--(Marketwire - November 4, 2008) - HemaQuest Pharmaceuticals today announced that
the U.S. Food and Drug Administration (FDA) has awarded the company orphan
drug designations for sickle...